ScripsAmerica Reports 126% Quarterly Revenue Growth YoY During Q1 2014

Company Records Over $5 Million in Revenue During Q1 2014 and CEO Comments on Revenue Recognition

TYSONS CORNER, VA--(Marketwired - May 21, 2014) - ScripsAmerica Inc. (OTCBB: SCRC) today announced the filing of its 10Q for the quarter that ended March 31, 2014.

The Company reported $5,097,000 in revenue during Q1 2014 compared to $2,256,000 in Q1 2013, marking a 126% increase in quarterly revenue year over year. ScripsAmerica's 2014 first quarter revenue from operations as reported in the 'Statement of Operations' in the Company's latest 10Q filing was $823,859, marking an increase of 187% over the same period in 2013 when it was reported at $287,374.

Gross profit during Q1 2014 was $598,000 compared to a loss of $11,000 for Q1 2013. The Company generated $3,687,222 in revenue from its joint government contract during the first quarter of 2014 compared to $1,955,345 during Q1 2013. This increase of $1,731,877 in quarterly revenue equals an 88% YoY growth rate for this contract.

This revenue is reported on page 30 of ScripsAmerica's 10Q in the 'Products Sold' column in the 'Revenue Net' section in addition to $793,000 in Q1 revenue from its pharmaceutical partner. Due to financial reporting requirements, ScripsAmerica can report only the net profits from its joint government contract and pharmaceutical partner, Wholesale Rx and not its top line revenue.

Commenting on ScripsAmerica's first quarter results, CEO Bob Schneiderman stated, "ScripsAmerica is pleased to report very positive financial results during the first quarter of 2014, marking the strong start we expected for what we believe will be a breakout year for the Company and its shareholders.

"It is also very important to remind the investment community that the Company's necessary accounting method has a significant impact on the reportable revenues from our government joint venture and Wholesale Rx investment, both of which will continue to generate revenue and profits for ScripsAmerica.

"The Company experienced tremendous growth across the business from our pharmaceutical equity venture with WRx to receiving an initial order for RapiMed in Asia as well as taking on the management of a specialty pharmacy that generated revenues of $494,643 in March before nearly doubling to $958,234 in April.

"We expect to see continued revenue growth in the upcoming quarters from our managed specialty pharmacy, equity ventures with WRx and PIMD International and our joint government contract which should lead to a sizeable increase in shareholder value."

About ScripsAmerica, Inc.

ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Seal Point Consulting 888-959-7095 Email Contact

ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more ScripsAmerica (CE) Charts.
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more ScripsAmerica (CE) Charts.